Solid Biosciences Inc. Interest Expense Nonoperating
Solid Biosciences Inc. (SLDB) reported Interest Expense Nonoperating of -$203.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Solid Biosciences Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $5.00K, a 93.33% decline year-over-year.
- Solid Biosciences Inc. interest expense nonoperating for the quarter ending 2025-09-30 was -$336.00K, a 509.76% decline year-over-year.
- Solid Biosciences Inc. interest expense nonoperating for the quarter ending 2025-06-30 was $60.00K, a 31.82% decline year-over-year.
- Solid Biosciences Inc. interest expense nonoperating for the quarter ending 2025-03-31 was $68.00K, a 28.42% decline year-over-year.
- Solid Biosciences Inc. interest expense nonoperating for fiscal 2025 was -$203.00K, a 159.71% decline from fiscal 2024.
- Solid Biosciences Inc. interest expense nonoperating for fiscal 2024 was $340.00K, a 22.73% decline from fiscal 2023.
- Solid Biosciences Inc. interest expense nonoperating for fiscal 2023 was $440.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$331.00K derived: sum of 2 quarters · filed 2026-03-19 | -$271.00K derived: sum of 3 quarters · filed 2026-08-06 | -$203.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$336.00K 10-Q · filed 2025-11-03 | -$276.00K derived: sum of 2 quarters · filed 2026-08-06 | -$208.00K 10-Q · filed 2025-11-03 | -$133.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $60.00K 10-Q · filed 2026-08-06 | $128.00K 10-Q · filed 2026-08-06 | $203.00K derived: sum of 3 quarters · filed 2026-08-06 | $285.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $68.00K 10-Q · filed 2026-05-12 | $143.00K derived: sum of 2 quarters · filed 2026-05-12 | $225.00K derived: sum of 3 quarters · filed 2026-05-12 | $313.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $157.00K derived: sum of 2 quarters · filed 2026-03-19 | $245.00K derived: sum of 3 quarters · filed 2026-03-19 | $340.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $82.00K 10-Q · filed 2025-11-03 | $170.00K derived: sum of 2 quarters · filed 2025-11-03 | $265.00K 10-Q · filed 2025-11-03 | $366.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $88.00K 10-Q · filed 2025-08-12 | $183.00K 10-Q · filed 2025-08-12 | $284.00K derived: sum of 3 quarters · filed 2025-08-12 | $390.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $95.00K 10-Q · filed 2025-05-15 | $196.00K derived: sum of 2 quarters · filed 2025-05-15 | $302.00K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $207.00K derived: sum of 2 quarters · filed 2025-03-06 | $440.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $106.00K 10-Q · filed 2024-11-06 | $339.00K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |